HEPA
Hepion Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.10
−1.45%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.10
From 52W high−18.32%
Volume5332.00
Market cap$1.19M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$0.10
From 52W high
−18.32%
Volume
5332.00
Market cap
$1.19M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
P/E (TTM)
—
RSI (14)
52.5
MomentumView details →
1D Return
−1.45%
YTD Return
+70.17%
SummaryUpdated Jun 1, 2026
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in Edison, New Jersey. Originally incorporated as ContraVir Pharmaceuticals, the company rebranded to Hepion Pharmaceuticals in July 2019 to better reflect its focus on liver disease therapeutics. The company went public in February 2014 and has since dedicated its efforts to developing innovative drug therapies for chronic liver diseases, with its lead candidate Rencofilstat currently in clinical development for treating non-alcoholic steatohepatitis (NASH) and other liver conditions.
Similar companies
Latest newsMore news →
Hepion Pharmaceuticals said it anticipates filing an IND for GV104 and beginning the path toward a Phase 2 study in 2027.15h agoThe FDA’s Division of Psychiatry issued written responses to Gravitas Life Sciences’ pre-IND meeting request for GV104, stating that existing nonclinical and manufacturing data may be cross-referenced and that the planned Phase 2 proof-of-concept design is generally appropriate.15h ago